RxDoctor Payments Data

James Brown, MD

Family Medicine · Chatsworth, GANPI 1285620831

Payments from drug & device makers

$517in general payments, 2019–2025

Across 27 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$148
  • Sanofi-aventis U.S. LLC$132
  • AbbVie$84
  • Lilly USA, LLC$31
  • Alkermes, Inc.$25
  • Abbott$23
  • plus $75 from 5 others

What the payments were for

  • Food & beverage$517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$517 in reported general payments places this provider in the 45th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$215,353
Medicare patients
384
Services billed
5,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide188$253,188
JardianceEmpagliflozin45$66,687
OzempicSemaglutide46$61,802
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$61,390
RybelsusSemaglutide34$54,601
EliquisApixaban52$50,986
Tresiba Flextouch U-200Insulin Degludec33$42,112
XareltoRivaroxaban31$33,461
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$31,318
TrulicityDulaglutide19$23,435
MyrbetriqMirabegron17$22,326
TradjentaLinagliptin19$22,025
Novolog FlexpenInsulin Aspart45$19,101
Soliqua 100-33Insulin Glargine/Lixisenatide15$16,988
LinzessLinaclotide21$16,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$31$276,623207 claims
Novo NordiskOzempic, Rybelsus$148$116,40380 claims
GSKTrelegy Ellipta, Breo Ellipta$17$72,32390 claims
AbbVieLinzess, Synthroid$84$19,72966 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$132$16,98815 claims
AstraZenecaSymbicort$19$7,34116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Chatsworth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →